AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20560909
Drug: Fluticasone proprionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone proprionate (FP) 1000 μg
Trial: 18633020
Drug: Intraoperative IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative IV dexamethasone 8 mg and ondansetron 4 mg, followed by 8 mg oral disintegrating ondansetron tablet on discharge and in the morning of postoperative days 1 and 2.
Trial: 18633020
Drug: Intraoperative IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative IV ondansetron 4 mg (control group).
Trial: 15863529
Drug: Testosterone patch
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch (300 mug/d)
Trial: 2405109
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 75 mg/m2 and doxorubicin (Dox) 50 mg/m2 intravenously every 3 weeks
Trial: 2405109
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) and doxorubicin (Dox) as neoadjuvant therapy
Trial: 2405109
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) and doxorubicin (Dox) as sole therapy
Trial: 2405109
Drug: Multimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality therapy (CT followed by surgery or radiation therapy)
Trial: 7437258
Drug: Prolintane (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolintane (15 mg)
Trial: 7437258
Drug: Prolintane (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolintane (30 mg)
Trial: 7437258
Drug: Pemoline (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline (60 mg)
Trial: 7437258
Drug: Pemoline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline (100 mg)
Trial: 30388242
Drug: Supplemental protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental protein feeding (four commercially available protein supplements, wildflower pollen supplement)
Trial: 25281275
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control strategy (including electrical cardioversion and pharmacotherapy)
Trial: 20571180
Drug: Eszopiclone co-administered
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone co-administered with fluoxetine (ESZ+FLX)
Trial: 20571180
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with fluoxetine (PBO+FLX)
Trial: 15763646
Drug: Soy capsules
RxNorm normalized name: Nature's Way Estrosoy Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy capsules
Trial: 2678162
Drug: VALERINA NATT
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VALERINA NATT (valerian preparation)
Trial: 31849040
Drug: Inspiratory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory oxygen fraction of 0.80 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Trial: 31849040
Drug: Inspiratory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory oxygen fraction of 0.30 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Trial: 24635002
Drug: Short-term Psychoanalytic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term Psychoanalytic Child Therapy (PaCT), 20-25 sessions
Trial: 24635002
Drug: Short-term Psychoanalytic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term Psychoanalytic Child Therapy (PaCT)
Trial: 18083471
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg lornoxicam infusion 30 minutes before skin incision
Trial: 18083471
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion immediately after skin closure (control group)
Trial: 16128938
Drug: Tenatoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 40 mg once daily
Trial: 14585672
Drug: New TBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New TBE vaccine
Trial: 14585672
Drug: Formerly licensed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formerly licensed TBE vaccine
Trial: 9076651
Drug: Methadone formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone formulation change
Trial: 6205336
Drug: salm-calcitonin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salm-calcitonin and polychemo-therapy or hormonal treatment
Trial: 6205336
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no calcitonin therapy)
Trial: 30694881
Drug: Milk thistle
RxNorm normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk thistle (150 mg to 300 mg twice a day)
Trial: 28343976
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (25 Gy in ten daily fractions of 2·5 Gy)
Trial: 26536022
Drug: Subcutaneous apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous apomorphine (1-6 mg per dose, mean 3.4 mg) administered 3 times at 2-hour intervals
Trial: 21233014
Drug: TPF (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF (docetaxel 75 mg/m², cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 4 days)
Trial: 21233014
Drug: PF (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF (cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 5 days)
Trial: 15389416
Drug: Low-energy-dense salad
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy-dense salad (0.33 kcal/g) small portion (150 g)
Trial: 15389416
Drug: Low-energy-dense salad
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy-dense salad (0.33 kcal/g) large portion (300 g)
Trial: 15389416
Drug: High-energy-dense salad
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy-dense salad (1.33 kcal/g) small portion (150 g)
Trial: 15389416
Drug: High-energy-dense salad
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy-dense salad (1.33 kcal/g) large portion (300 g)
Trial: 12090907
Drug: Fosinopril monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril monotherapy (20 mg daily for 30 months)
Trial: 12090907
Drug: Hydrochlorothiazide and
RxNorm normalized name: hydrochlorothiazide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide and hydralazine combination
Trial: 9520174
Drug: COL‐1492 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL‐1492 gel
Trial: 8061724
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (11.1 mumol/kg/min) + Amino acids infusion (3.33 mg/kg/min for last 4 hours)
Trial: 8061724
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (Lipovenös, 10% 10 ml/min for 7.5 h) + Amino acids infusion (for last 4 hours)
Trial: 8061724
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (10% 10 ml/min) + Amino acids infusion (for last 4 hours)
Trial: 959765
Drug: Exogenous hormones
RxNorm normalized name: Exogenous hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous hormones (secretin and CCK)
Trial: 28719287
Drug: DPIV formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPIV formulations (1 or 4 μg with aluminum hydroxide or 1 μg with AS01E or AS03B)
Trial: 28719287
Drug: DPIV formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPIV formulations
Trial: 26553086
Drug: Zolpidem (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (10 mg/PO/bed time)
Trial: 24119468
Drug: FIR-radiated therapy
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIR-radiated therapy (40-minute radiation at the major lesion site or anastomosed site three times a week)
Trial: 24119468
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (free-radiated usual therapy)
Trial: 24119468
Drug: FIR-radiated therapy
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIR-radiated therapy
Trial: 17526179
Drug: Acupoint drug-finger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint drug-finger pressing (ADFP) on Ganshu (BL18), Danshu (BL19), Weishu (BL21), and Pishu (BL20) acupoints, 15 min each time, twice per day for 3 weeks.
Trial: 17526179
Drug: Acid-inhibitory and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-inhibitory and gastrokinetic drugs (omeprazole 20 mg once every 12 hours and cisapride 10 mg thrice daily before meals) for 3 weeks.
Trial: 9663911
Drug: Home blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home blood pressure monitoring for 2 weeks (6 work days, duplicate measurements, twice daily)
Trial: 31876052
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Echinacea angustifolia root extract twice daily for 7 days
Trial: 31876052
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily for 7 days
Trial: 31389880
Drug: Surgical antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical antibiotic prophylaxis before hand surgery
Trial: 25045795
Drug: Cathejell lubricant
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathejell lubricant with lidocaine 12.5g administered immediately before cystoscopy
Trial: 17327338
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg q.d. and 60 mg b.i.d.
Trial: 16083193
Drug: Creatine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplement (5 g with orange solution 15 g, twice per day for 7 days)
Trial: 16083193
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (orange solution only)
Trial: 8922007
Drug: Subcutaneous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous lidocaine (SQL) pretreatment
Trial: 1550365
Drug: D‐penicillamine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐penicillamine (maximum dose of 750 mg/d)
Trial: 2931846
Drug: Chrysanol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chrysanol (1.5 ml of a 5% solution)
Trial: 2931846
Drug: Myochrysine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myochrysine (50 mg, 25 mg metallic gold once a week)
Trial: 28169258
Drug: Adjunctive photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive photodynamic therapy (PDT) using 810 nm diode laser and Indocyanine green as photosensitizer
Trial: 25453731
Drug: Statins (3‐hydroxy‐3‐methylglutaryl‐coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors) ± ezetimibe
Trial: 12002352
Drug: Intravesical oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical oxybutynin (5 mg/30 ml three times daily)
Trial: 9813559
Drug: L‐NMMA (nitric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (nitric oxide synthase inhibitor)
Trial: 7653804
Drug: Alfentanil 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min during CPB (normothermic)
Trial: 7653804
Drug: Alfentanil 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min during CPB (hypothermic)
Trial: 7653804
Drug: Alfentanil 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min (nonbypass group)
Trial: 2496420
Drug: Placebo gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gum (0 mg)
Trial: 828982
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: saline solution (1000‐1500 ml), glucose (100‐150 g), and amino acids (15‐30 g) per day
Trial: 828982
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: 40‐50 Cal/kg per day (dextrose about 15 g/kg per day), about 2 g of amino acids/kg/day and about 40‐50 ml water/kg/day
Trial: 828982
Drug: Hyperalimentation (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperalimentation (both treatments sequentially)
Trial: 29154057
Drug: Far-infrared ray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far-infrared ray (FIR) patches applied to 98 MTrPs for 24 hours in the intervention group (61 patients)
Trial: 29154057
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches applied to 91 MTrPs in the control group (57 patients)
Trial: 24458801
Drug: Rosuvastatin (RSV)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (RSV) 10 mg/d plus Ezetimibe (EZT) 10 mg/d
Trial: 24458801
Drug: Rosuvastatin (RSV)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (RSV) 10 mg/d and Ezetimibe (EZT) 10 mg/d
Trial: 21330640
Drug: Valsartan (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (320 mg daily)
Trial: 19387176
Drug: Sugammadex (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (16 mg/kg) administered 3 min after rocuronium (1.2 mg/kg)
Trial: 17291177
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of an inert placebo described as a suspected environmental toxin
Trial: 14699004
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ramipril (10 mg/d) and atorvastatin (40 mg/d)
Trial: 8445234
Drug: alpha-interferon with
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha-interferon with or without steroid priming
Trial: 3725503
Drug: Standard magnesium-aluminum
RxNorm normalized name: Magnesium Aluminum Silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard magnesium-aluminum hydroxide antacids at a dose of 0.5 mL/kg per dose
Trial: 30630801
Drug: Breast-conserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving therapy integrated with neoadjuvant chemotherapy
Trial: 28667881
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy (wait-list group)
Trial: 18507868
Drug: BB therapy
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BB therapy with thrice-daily insulin aspart and once-daily basal insulin (BB group)
Trial: 18507868
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with twice-daily biphasic insulin analogue (30 Mix group)
Trial: 10379622
Drug: Higher nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher nicotine yield cigarettes (1.1 mg nicotine yield)
Trial: 10379622
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine yield cigarette (0.05 mg nicotine yield)
Trial: 8950781
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) with low estrogen formulations containing norgestimate or gestodene
Trial: 1850722
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose chemotherapy (60 mg/m2 doxorubicin and 500 mg/m2 5-fluorouracil every 3 weeks)
Trial: 1850722
Drug: 131I antiferritin
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I antiferritin administration every 8 weeks
Trial: 1850722
Drug: 131I antiferritin
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I antiferritin administration
Trial: 21779745
Drug: Tooth/implant supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth/implant supported restoration
Trial: 21779745
Drug: Implant only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant only restoration
Trial: 19508580
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel applied to the wound twice a day for 60 days after removal of stitches
Trial: 12819247
Drug: High-dose dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dialysis
Trial: 12819247
Drug: Standard-dose dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose dialysis
Trial: 12490682
Drug: Dose and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and flux interventions
Trial: 7616311
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (20 mg/kg body wt) in young adult women
Trial: 7616311
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (2.5 g/kg diet) in Sprague-Dawley rats
Trial: 7616311
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (3 g/kg diet) in guinea pigs
Trial: 203998
Drug: Corticotropin (ACTH)
RxNorm normalized name: corticotropin Injectable Solution [ACTH Gel]
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticotropin (ACTH) 80 units intramuscularly daily
Trial: 203998
Drug: Hydrocortisone 400
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 400 mg infused intravenously over 24 hours
Trial: 22500381
Drug: Erzhi Tiangui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erzhi Tiangui Granule combined with Western medicine
Trial: 16225522
Drug: Lidocaine suppositories
RxNorm normalized name: lidocaine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine suppositories (60 mg) applied 1 or 2 hours before biopsy
Trial: 16225522
Drug: Lidocaine suppositories
RxNorm normalized name: lidocaine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine suppositories (60 mg) applied 1 hour before biopsy
Trial: 16225522
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel (2% - 200 mg) applied 10 minutes before biopsy
Trial: 10432030
Drug: Vaccine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (30 microg each of gB2 and gD2, administered at months 0, 1, and 6)
Trial: 8642806
Drug: Rilmenidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine (2 mg)
Trial: 2155756
Drug: Otomize spray
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Otomize spray (neomycin/dexamethasone), administered 3 times daily for 10 days
Trial: 2155756
Drug: Otosporin drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otosporin drops (neomycin/polymyxin B/hydrocortisone), administered 3 times daily for 10 days
Trial: 7435249
Drug: Melperone, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone, 50 mg i.v.
Trial: 26446479
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg kg(‐1) hr(‐1))
Trial: 17846068
Drug: Facio‐oral tract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facio‐oral tract therapy for three weeks (15 sessions of 1 hour each)
Trial: 15142200
Drug: Esomeprazole 2
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 2 x 20 mg
Trial: 15142200
Drug: Esomeprazole 1
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 1 x 40 mg
Trial: 12575590
Drug: Huancongdan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huancongdan capsule (HCDC)
Trial: 9389288
Drug: Intranasal glucocorticoid
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glucocorticoid (beclomethasone dipropionate, 400 microg/day)
Trial: 8317687
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg acetylsalicylic acid (ASA) daily